Improvement of Pulmonary Insufficiency After Aortic Dissection With Sivelestat Sodium

Aortic Dissection Clinical Trial

— IPIADSS  

Official title:

A Randomized Controlled Study of Sivelestat Sodium in Improving Pulmonary Insufficiency After Aortic Dissection Arch Surgery Under Hypothermic Circulatory Arrest

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05343338
• Other study ID #: XJTU1AF2021CRF-017
• Status: Not yet recruiting
• Phase: N/A
• Start date: April 20, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: April 2022
• Source: First Affiliated Hospital Xi'an Jiaotong University
• Contact: Tao Shi, PhD
• Phone: 0086-029-85323601
• Email: shi2009tao[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aortic dissection (AD) is one of the most dangerous cardiovascular emergencies, with rapid onset, rapid progression, high fatality rate, and a variety of life-threatening complications. Acute lung injury (ALI) caused by AD is an important cause of many adverse outcomes. Studies have confirmed that 34.9% to 53.8% of AAD patients have ALI before surgery, and Impaired preoperative lung function may lead to worse oxygenation after AD surgery. The pathophysiological mechanism of AD-induced ALI is complex. A variety of preoperative and intraoperative risk factors can induce or aggravate ALI, such as ischemia-reperfusion injury, deep hypothermic circulatory arrest, and inflammatory reactions. At present, the clinical use of improved surgery, cardiopulmonary bypass perfusion, early anti-inflammatory treatment, and protective lung ventilation can reduce and improve perioperative ALI to a certain extent, but it is still not ideal. In recent years, inhibition of neutrophil activation and aggregation, and reduction of neutrophil elastase activity as targets for the treatment of inflammatory injury have also become an important clinical treatment measure, in order to further reduce the body's inflammatory response to improve and alleviate ALI. Sivelestat sodium, as a neutrophil elastase inhibitor, is the only approved therapeutic drug for ALI/ acute respiratory distress syndrome (ARDS) in the world. It is precisely by reducing the inflammatory infiltration of neutrophils and inhibiting neutrophil elastase activity, thereby exerting a certain protective effect on the lungs. The study takes patients with AD surgery as the research object. On the basis of not terminating and changing the original treatment plans, sivelestat sodium was added in the perioperative period to observe the incidence, and severity of ALI/ARDS in the perioperative period. It aims to explore the efficacy and safety of sivelestat sodium in the treatment of pulmonary insufficiency after AD arch surgery under hypothermic circulatory arrest.

Description:

The study is a single-center, randomized, open-label, blank-controlled study, and designs to recruit AD perioperative patients admitted to the Cardiovascular Surgery Department of the First Affiliated Hospital of Xi'an Jiaotong University, between January 1, 2022 and December 31, 2022, with a total of 168 cases. After the patients who met the inclusion and exclusion criteria signed the informed consent, they were randomly assigned to the experimental group and the control group at a 1:1 ratio, with 84 cases in each group. The experimental group is additionally given sivelestat sodium in the perioperative period on the basis of the original treatment. The study was divided into two phases, the screening phase and the treatment phase. The screening period was from admission to the day of surgery to determine whether patients were suitable for the study. The treatment period is from the induction of anesthesia to the day of being transferred out from the ICU. It is necessary to complete the detailed treatment plan, and drug dosage, intraoperative and postoperative serological examinations, imaging examinations, and the patient's mechanical ventilation and oxygenation index data. Sivelestat sodium was used during and after operation in the experimental group, and the end time of administration was 96 hours after admission to the ICU. During the treatment with sivelestat sodium, the patient's original treatment plan will not be terminated or affected. The control group only received the original clinical diagnosis and treatment and clinical management. Study endpoints were defined as the day of ICU transfer, follow-up until discharge, or discontinuation/termination during the study period, or patient withdrawal from the study for any reason. During the study period, doctors will provide supportive treatment according to clinical indications, medication instructions and specifications. In the event of an adverse event, the doctor may make adjustments to the medication dose and treatment duration. The main observation indicators were the incidence of moderate to severe respiratory insufficiency (PaO2/FiO2 ≤ 200mmHg) at 24, 72, and 120 hours after surgery, on the day of transfer out of ICU, and discharge. The efficacy and safety of the drug were evaluated.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 168
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients aged from 18 to 70 years old;
• Patients undergoing aortic dissection arch surgery under hypothermic circulatory arrest;
• Weight from 45 to 90kg;
• ASA cardiac function class from II to IV;
• Patients who can understand and comply with the requirements of the protocol and volunteer to participate.

Exclusion Criteria:

• Patients participating in other clinical studies;
• Patients with serious lack of medical data;
• Women who are pregnant or may become pregnant or breastfeeding;
• Patients with severe lung diseases, such as end-stage chronic obstructive pulmonary disease, chronic interstitial lung disease, etc.;
• Patients with malignant tumors;
• Preoperative oxygenation index PaO2/FiO2=200mmHg;
• Patients with EUROScoreII mortality risk < 3%;
• Patients with APACHE II score = 21;
• Patients who are judged by the researchers to be unsuitable for inclusion, such as those with mental illnesses.

Related Conditions & MeSH terms

• Acute Lung Injury
• Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
• Aneurysm, Dissecting
• Aortic Dissection
• Lung Injury
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn

Intervention

Drug:
• Sivelestat sodium
After dissolving sivelestat sodium with 0.9% sodium chloride injection, dilute the 1-day dose (4.8 mg/kg) with 50 mL of 0.9% sodium chloride injection and continue intravenously at a rate of 0.2 mg/kg/h for administration. The start time of administration was after induction of anesthesia, and at the same time, the extracorporeal circulation circuit is prefilled with 100 mg. The end time is 48 hours after admission to the ICU.

Locations

Country	Name	City	State
China	First Affiliated Hospital of Xian Jiaotong University	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital Xi'an Jiaotong University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of respiratory insufficiency	Incidence of postoperative moderate to severe respiratory insufficiency (PaO2/FiO2 = 200mmHg).	24 hours after surgery
Primary	Incidence of respiratory insufficiency	Incidence of postoperative moderate to severe respiratory insufficiency (PaO2/FiO2 = 200mmHg).	72 hours after surgery
Primary	Incidence of respiratory insufficiency	Incidence of postoperative moderate to severe respiratory insufficiency (PaO2/FiO2 = 200mmHg).	120 hours after surgery
Secondary	Incidence of prolonged mechanical ventilation	Mechanical ventilation time > 72h	120 hours after surgery
Secondary	Levels of neutrophil elastase activity	Preoperative and postoperative blood neutrophil elastase activity levels.	24 hours after surgery
Secondary	Levels of neutrophil elastase activity	Preoperative and postoperative blood neutrophil elastase activity levels.	72 hours after surgery
Secondary	Levels of neutrophil elastase activity	Preoperative and postoperative blood neutrophil elastase activity levels.	Date of discharge from Cardiovascular Surgery ICU for any reason, or assessed up to 4 weeks
Secondary	White blood cell count	Blood routine examination WBC count	24 hours after surgery
Secondary	White blood cell count	Blood routine examination WBC count	Date of discharge from Cardiovascular Surgery ICU for any reason, or assessed up to 4 weeks
Secondary	plasma C-reactive protein	serial plasma high-sensitivity CRP	24 hours after surgery
Secondary	plasma C-reactive protein	serial plasma high-sensitivity CRP	Date of discharge from Cardiovascular Surgery ICU for any reason, or assessed up to 4 weeks
Secondary	serum procalcitonin	Serum PCT level	24 hours after surgery
Secondary	serum procalcitonin	Serum PCT level	Date of discharge from Cardiovascular Surgery ICU for any reason, or assessed up to 4 weeks
Secondary	serum interleukin-6	Serum IL-6 level	24 hours after surgery
Secondary	serum interleukin-6	Serum IL-6 level	Date of discharge from Cardiovascular Surgery ICU for any reason, or assessed up to 4 weeks